- Home
- ADCT vs TACO Comparison
ADCT vs TACO Comparison
Compare ADCT & TACO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- TACO
- Stock Information
- Founded
- ADCT 2011
- TACO 2024
- Country
- ADCT Switzerland
- TACO United States
- Employees
- ADCT N/A
- TACO N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- TACO Blank Checks
- Sector
- ADCT Health Care
- TACO Finance
- Exchange
- ADCT Nasdaq
- TACO Nasdaq
- Market Cap
- ADCT 380.2M
- TACO 393.9M
- IPO Year
- ADCT 2020
- TACO 2025
- Fundamental
- Price
- ADCT $3.95
- TACO $10.19
- Analyst Decision
- ADCT Strong Buy
- TACO
- Analyst Count
- ADCT 6
- TACO 0
- Target Price
- ADCT $7.60
- TACO N/A
- AVG Volume (30 Days)
- ADCT 860.1K
- TACO 456.5K
- Earning Date
- ADCT 11-10-2025
- TACO 01-01-0001
- Dividend Yield
- ADCT N/A
- TACO N/A
- EPS Growth
- ADCT N/A
- TACO N/A
- EPS
- ADCT N/A
- TACO N/A
- Revenue
- ADCT $77,246,000.00
- TACO N/A
- Revenue This Year
- ADCT $11.78
- TACO N/A
- Revenue Next Year
- ADCT $4.83
- TACO N/A
- P/E Ratio
- ADCT N/A
- TACO N/A
- Revenue Growth
- ADCT 15.73
- TACO N/A
- 52 Week Low
- ADCT $1.05
- TACO $10.16
- 52 Week High
- ADCT $4.80
- TACO $11.32
- Technical
- Relative Strength Index (RSI)
- ADCT 44.05
- TACO N/A
- Support Level
- ADCT $3.92
- TACO N/A
- Resistance Level
- ADCT $4.80
- TACO N/A
- Average True Range (ATR)
- ADCT 0.23
- TACO 0.00
- MACD
- ADCT -0.06
- TACO 0.00
- Stochastic Oscillator
- ADCT 4.32
- TACO 0.00
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About TACO Berto Acquisition Corp. Ordinary Shares
Berto Acquisition Corp is a blank check company.